Aurora Spine Corporation Issued Patent by USPTO For Its Interlaminar Single Implant Technology For Motion Preservation or Fusion
13 June 2022 - 9:15PM
Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV:
ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative
medical devices that improve spinal surgery outcomes, today
announced the issuance of United States Patent No: 11,331,199
entitled "Spinal Implant for Motion Preservation or Fusion." This
patent covers Aurora's ZIPFlex™ Technology for a minimally invasive
posterior interlaminar implant for motion preservation that could
be adapted into a fusion or non-fusion device while implanted in a
patient via a small modular attachment.
A Media Snippet accompanying this announcement is available by
clicking on the image or link below:
This new patent covers interlaminar motion-preserving and fusion
implants in one device that could treat lumbar spinal degenerative
diseases, such as spinal stenosis. Over the last 50 years, spinal
fusion has become the gold standard for treating several
degenerative spinal disorders. Motion preservation surgeries are
also popular since they avoid total fusion. A ZIPFlex
Technology-based implant could be implanted as a motion
preservation device and months or years later could be easily
converted from motion preservation device to a fusion implant via a
minor keyhole procedure by adding a blocker element at the center
of the main body. Patented features of ZIPFlex™ include
individually adjustable anchors to prevent implant migration and
unnecessary bone removal to fit the implant. Aurora's ZIPFlex is
the first technology to offer an all-in-one approach to providing
viable options for treating patients with back pain.
"Some of the difficulty with traditional spinal fusion systems
is that stabilization or additional fusion may be required
intraoperatively, particularly to protect adjacent levels after
spinal surgery and to protect degenerative segments following
decompressive surgery," said Steven Falowski, M.D.,
Director of Functional Neurosurgery at Argires-Marotti
Neurosurgical Associates of Lancaster, PA. "Aurora received the
ZIPFlex patent, with its proprietary Modular In-Situ Fusion Block,
a device that provides the surgeon with the ability to
determine whether to stabilize or fuse a patient
intraoperatively during the procedure or to allow motion
preservation. This is a major step forward in delivering the
best options long term for your patients.”
Mr. Trent Northcutt, President and Chief Executive Officer of
Aurora Spine, stated, "As our IP portfolio continues to grow, so
does the positive impact we can make for our physician customers
and their patients. With this latest patent grant from the USPTO,
we have further strengthened our value proposition and the depth
and breadth of our portfolio of minimally invasive interlaminar
devices.”
Mr. Laszlo Garamszegi, Chief Technology Officer of Aurora Spine,
added, "We are excited to receive this patent covering the
technology of our proposed ZIPFlex device. Aurora’s motto,
“Simplifying the Complex” is the focus of every product we create.
The “two-in-one” ZIPFlex device patent is another example of how
the company is working to build upon its IP and offer our customers
highly technical products that contain an 'ease of use'
element.”
About Aurora Spine
Aurora Spine focuses on bringing new solutions to the spinal
implant market through innovative, minimally invasive, regenerative
spinal implant technologies. Additional information can be accessed
at www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that
involves substantial known and unknown risks and uncertainties,
most of which are beyond the control of Aurora Spine, including,
without limitation, those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Information" in
Aurora Spine's final prospectus (collectively, "forward-looking
information"). Forward-looking information in this news release
includes information concerning the proposed use and success of the
company's products in surgical procedures. Aurora Spine cautions
investors of Aurora Spine's securities about important factors that
could cause Aurora Spine's actual results to differ materially from
those projected in any forward-looking statements included in this
news release. Any information that expresses or involves
discussions as to expectations, beliefs, plans, objectives,
assumptions, or future events or performance are not historical
facts and may be forward-looking and may involve estimates,
assumptions, and uncertainties that could cause actual results or
outcomes to differ unilaterally from those expressed in such
forward-looking statements. No assurance can be given that the
expectations set out herein will prove to be correct and,
accordingly, prospective investors should not place undue reliance
on these forward-looking statements. These statements speak only as
of the date of this press release, and Aurora Spine does not assume
any obligation to update or revise them to reflect new events or
circumstances.
Contact:
Aurora Spine Corporation
Trent NorthcuttPresident and Chief Executive Officer(760)
424-2004
Chad ClouseChief Financial Officer(760)
424-2004www.aurora-spine.com
Adam LowensteinerLYTHAM PARTNERS, LLCPhoenix | New
YorkTelephone: 646-829-9700asapf@lythampartners.com
Aurora Spine (TSXV:ASG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurora Spine (TSXV:ASG)
Historical Stock Chart
From Apr 2023 to Apr 2024